Cargando…

Clinical Characteristics and Outcomes of Extracorporeal Membrane Oxygenation Support in COVID-19: Retrospective Study of Single Center Experience

PURPOSE: The use of extracorporeal membrane oxygenation (ECMO) support is increasingly used in the management of COVID-19-related acute respiratory distress syndrome (ARDS). The effect of ECMO for patients with severe ARDS in the context of COVID-19 is unclear. This study is to summarize the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurihara, C., Manerikar, A., Kandula, V., Bharat, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979393/
http://dx.doi.org/10.1016/j.healun.2021.01.1121
_version_ 1783667274976067584
author Kurihara, C.
Manerikar, A.
Kandula, V.
Bharat, A.
author_facet Kurihara, C.
Manerikar, A.
Kandula, V.
Bharat, A.
author_sort Kurihara, C.
collection PubMed
description PURPOSE: The use of extracorporeal membrane oxygenation (ECMO) support is increasingly used in the management of COVID-19-related acute respiratory distress syndrome (ARDS). The effect of ECMO for patients with severe ARDS in the context of COVID-19 is unclear. This study is to summarize the clinical features, and outcomes of patients with severe ARDS due to COVID-19 treated with ECMO. We analyzed the incidence of morbidity including ischemic/hemorrhagic stroke, gastrointestinal bleeding, pump malfunction, oxygenator dysfunction, infection during VV ECMO. We also compared COVID ECMO patients to non COVID-19 ECMO patients. METHODS: This is a retrospective review of an institutional ECMO database. We included consecutive patients from January 2015 through July 2020. 138 patients (mean age, 47.0 ± 14.4 y) with respiratory failure who underwent VV ECMO implantation were included in this study. Patients were stratified into two cohorts: those with COVID-19 or non COVID-19. RESULTS: Patients with COVID-19 had higher body mass index (33.4 ± 5.9 vs 28.8 ± 8.9, p<0.01), also had lower albumin level (2.7 ± 0.5 vs 3.1 ± 0.7, p<0.01). Patients with COVID-19 demonstrated not significantly lower survival rates (p=0.16). There was also no significant difference between 2 groups in incidence of acute kidney injury (p=0.17), dialysis (p=0.82), tracheostomy, (p=0.22), neurological dysfunction (p=0.19), gastrointestinal bleeding (p=0.42), oxygenator dysfunction (p=0.37), and sepsis (p=0.75). However, ECMO support days were significantly longer in COVID ECMO patients. (29.0 ± 27.5 vs 15.9 ± 19.6 days, p<0.01). CONCLUSION: These findings suggest that COVID related ARDS was not associated with a higher postoperative mortality rate than non COVID related ARDS patients, even though support days of ECMO was longer in those groups. ECMO should be considered for patients developing ARDS despite optimised care.
format Online
Article
Text
id pubmed-7979393
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-79793932021-03-23 Clinical Characteristics and Outcomes of Extracorporeal Membrane Oxygenation Support in COVID-19: Retrospective Study of Single Center Experience Kurihara, C. Manerikar, A. Kandula, V. Bharat, A. J Heart Lung Transplant 1004 PURPOSE: The use of extracorporeal membrane oxygenation (ECMO) support is increasingly used in the management of COVID-19-related acute respiratory distress syndrome (ARDS). The effect of ECMO for patients with severe ARDS in the context of COVID-19 is unclear. This study is to summarize the clinical features, and outcomes of patients with severe ARDS due to COVID-19 treated with ECMO. We analyzed the incidence of morbidity including ischemic/hemorrhagic stroke, gastrointestinal bleeding, pump malfunction, oxygenator dysfunction, infection during VV ECMO. We also compared COVID ECMO patients to non COVID-19 ECMO patients. METHODS: This is a retrospective review of an institutional ECMO database. We included consecutive patients from January 2015 through July 2020. 138 patients (mean age, 47.0 ± 14.4 y) with respiratory failure who underwent VV ECMO implantation were included in this study. Patients were stratified into two cohorts: those with COVID-19 or non COVID-19. RESULTS: Patients with COVID-19 had higher body mass index (33.4 ± 5.9 vs 28.8 ± 8.9, p<0.01), also had lower albumin level (2.7 ± 0.5 vs 3.1 ± 0.7, p<0.01). Patients with COVID-19 demonstrated not significantly lower survival rates (p=0.16). There was also no significant difference between 2 groups in incidence of acute kidney injury (p=0.17), dialysis (p=0.82), tracheostomy, (p=0.22), neurological dysfunction (p=0.19), gastrointestinal bleeding (p=0.42), oxygenator dysfunction (p=0.37), and sepsis (p=0.75). However, ECMO support days were significantly longer in COVID ECMO patients. (29.0 ± 27.5 vs 15.9 ± 19.6 days, p<0.01). CONCLUSION: These findings suggest that COVID related ARDS was not associated with a higher postoperative mortality rate than non COVID related ARDS patients, even though support days of ECMO was longer in those groups. ECMO should be considered for patients developing ARDS despite optimised care. Published by Elsevier Inc. 2021-04 2021-03-20 /pmc/articles/PMC7979393/ http://dx.doi.org/10.1016/j.healun.2021.01.1121 Text en Copyright © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle 1004
Kurihara, C.
Manerikar, A.
Kandula, V.
Bharat, A.
Clinical Characteristics and Outcomes of Extracorporeal Membrane Oxygenation Support in COVID-19: Retrospective Study of Single Center Experience
title Clinical Characteristics and Outcomes of Extracorporeal Membrane Oxygenation Support in COVID-19: Retrospective Study of Single Center Experience
title_full Clinical Characteristics and Outcomes of Extracorporeal Membrane Oxygenation Support in COVID-19: Retrospective Study of Single Center Experience
title_fullStr Clinical Characteristics and Outcomes of Extracorporeal Membrane Oxygenation Support in COVID-19: Retrospective Study of Single Center Experience
title_full_unstemmed Clinical Characteristics and Outcomes of Extracorporeal Membrane Oxygenation Support in COVID-19: Retrospective Study of Single Center Experience
title_short Clinical Characteristics and Outcomes of Extracorporeal Membrane Oxygenation Support in COVID-19: Retrospective Study of Single Center Experience
title_sort clinical characteristics and outcomes of extracorporeal membrane oxygenation support in covid-19: retrospective study of single center experience
topic 1004
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979393/
http://dx.doi.org/10.1016/j.healun.2021.01.1121
work_keys_str_mv AT kuriharac clinicalcharacteristicsandoutcomesofextracorporealmembraneoxygenationsupportincovid19retrospectivestudyofsinglecenterexperience
AT manerikara clinicalcharacteristicsandoutcomesofextracorporealmembraneoxygenationsupportincovid19retrospectivestudyofsinglecenterexperience
AT kandulav clinicalcharacteristicsandoutcomesofextracorporealmembraneoxygenationsupportincovid19retrospectivestudyofsinglecenterexperience
AT bharata clinicalcharacteristicsandoutcomesofextracorporealmembraneoxygenationsupportincovid19retrospectivestudyofsinglecenterexperience